News archive search
Search the Newsreel
Search stored headlines and summaries, then narrow the results by company, country, sector, industry, source or date.
- Showing
- 37–72
- Matches
- 104
- Sources here
- 17
- Companies here
- 8
Search results
Stored financial headlines
Active search
104 matching headlines
Ticker or company: SCRMain company stories
Search results
Matching headlines
External headlines link to their original source. Market context comes from stored weekly company data, not from an opinion about the article.
Declaration made pursuant to Article L. 233-8-II of the French Commercial Code and Article 223-16 of the General Regulation of the Autorité des Marchés Financiers
SCOR Information July 31, 2026 Declaration made pursuant to Article L. 233-8-II of the French Commercial Code and Article 223-16 of the General Regulation of the Autorité des Marchés Financiers Information relating to the total number of shares and voting rights comprising the share …
Sharemaestro market context Trend signal active 52 weeks +27.0% · Next-week setup positive 56.7%SCOR SE (SCRYY) (Q2 2026) Earnings Call Highlights: Strong Net Income and Solvency Ratio Amid ...
This article first appeared on GuruFocus. Release Date: July 30, 2026 For the complete transcript of the earnings call, please refer to the full earnings call transcript. Positive Points SCOR SE (SCRYY) reported a strong group net income of EUR409 million in the first …
Sharemaestro market context Trend signal active 52 weeks +27.0% · Next-week setup positive 56.7%SCOR announces the availability of its 2026 Interim Financial Report
SCOR Press release 30 July 2026 - N° 17 SCOR announces the availability of its 2026 Interim Financial Report SCOR ("SCOR" or the "Company") announces the availability and the filing with the French Autorité des marchés financiers of its Interim Financial Report for the …
Sharemaestro market context Trend signal active 52 weeks +27.0% · Next-week setup positive 56.7%Behzad Aghazadeh Holds Board Seat at Scribe Therapeutics with 16.37% Stake
Behzad Aghazadeh, through funds managed by Avoro, disclosed a 16.37% beneficial stake in Scribe Therapeutics, Inc. (SCTX) via a Schedule 13D filing on July 30, 2026. This stake includes IPO purchases, converted preferred shares, and open-market buys, with Aghazadeh also serving on Scribe's board. …
SCTX
main company
Sharemaestro market context
Stored weekly price path
4 weeks -4.2% · Next-week setup positive 58.5%
Second quarter 2026 results: EUR 171 million net income in Q2 2026, contributing to a net income of EUR 397 million in H1 2026
SCOR Press release 30 July 2026 - N° 16 Second quarter 2026 results EUR 171 million net income in Q2 2026, contributing to a net income of EUR 397 million in H1 2026 Group net income of EUR 171 million in Q2 2026 driven …
Sharemaestro market context Trend signal active 52 weeks +27.0% · Next-week setup positive 56.7%Scribe Therapeutics Announces Closing of Initial Public Offering, Full Exercise of Underwriters’ Option to Purchase Additional Shares, and Closing of the Concurrent Private Placement
Scribe Therapeutics Inc. announced the closing of its upsized initial public offering of 9,867,000 shares at $15.00 per share, which included the full exercise of the underwriters' option for additional shares. Concurrently, the company also completed a private placement of 500,000 shares to Sanofi. …
SCTX
main company
Sharemaestro market context
Stored weekly price path
4 weeks -4.2% · Next-week setup positive 58.5%
Latham Advises on Scribe Therapeutics’ US$155.51 Million IPO
Latham & Watkins LLP advised the underwriters in Scribe Therapeutics Inc.'s upsized initial public offering, which closed at US$155.51 million. The clinical-stage biotechnology company offered 9,867,000 shares at US$15 per share, including the underwriters' full exercise of their option for additional shares. Scribe Therapeutics' …
SCTX
main company
Sharemaestro market context
Stored weekly price path
4 weeks -4.2% · Next-week setup positive 58.5%
Jennifer Doudna’s Scribe Therapeutics Rockets at IPO
Scribe Therapeutics, co-founded by Nobel laureate Jennifer Doudna, saw its shares jump 44.3% on its first day of trading. The genetic-medicines company raised $128.7 million in its IPO, selling over 8.5 million shares at $15 each. This successful debut signals a continued rebound for …
SCTX
main company
Sharemaestro market context
Stored weekly price path
4 weeks -4.2% · Next-week setup positive 58.5%
Scribe aims for $96M IPO to fund clinical push for lipid-lowering genetic meds
Scribe Therapeutics plans to raise $96 million through an IPO to advance its genetic medicine pipeline, including its lead program STX-1150 for lowering cholesterol, with initial data expected in the first half of 2027. The company will allocate significant funds to clinical development of …
SCTX
main company
Sharemaestro market context
Stored weekly price path
4 weeks -4.2% · Next-week setup positive 58.5%
Scribe records upsized $129M IPO to bankroll lipid-lowering genetic meds
Scribe Therapeutics has successfully upsized its IPO, raising $128.7 million to advance its gene-editing pipeline focused on lipid-lowering therapies. The company's lead candidate, STX-1150, targets the PCSK9 gene for cardiovascular disease, with topline data expected in the first half of 2027. Scribe plans to …
SCTX
main company
Sharemaestro market context
Stored weekly price path
4 weeks -4.2% · Next-week setup positive 58.5%
Scribe Therapeutics Announces Pricing of Upsized Initial Public Offering
ALAMEDA, Calif., July 23, 2026 (GLOBE NEWSWIRE) -- Scribe Therapeutics Inc. (“Scribe Therapeutics”) (Nasdaq: SCTX), a clinical-stage biotechnology company engineering purpose-built in vivo CRISPR technologies designed to extend healthy lifespan through disease prevention and durable therapeutic intervention, today announced the pricing of its upsized …
SCTX
main company
Sharemaestro market context
Stored weekly price path
4 weeks -4.2% · Next-week setup positive 58.5%
Scribe secures $129M in a rare gene editing IPO
This story was originally published on BioPharma Dive. To receive daily news and insights, subscribe to our free daily BioPharma Dive newsletter. Scribe Therapeutics has raised close to $129 millionin the first initial public offering for a developer of gene editing medicines in more …
SCTX
main company
Sharemaestro market context
Stored weekly price path
4 weeks -4.2% · Next-week setup positive 58.5%
Scripps unites television operations under Dean Littleton’s leadership
The E.W. Scripps Company has promoted Dean Littleton to president of media, consolidating leadership of its enterprise television and broadcast operations under him. This new role will see Littleton oversee all of Scripps’ television business, including local media, national Scripps Networks (ION and multicast/digital …
SSP
main company
Sharemaestro market context
Price below Trend Line
52 weeks +4.2%
Weekly Recap: Retransmission deal with DIRECTV and Q2 2026 earnings report
E.W. Scripps Company Class A (NASDAQ:SSP) successfully concluded a five-week DIRECTV blackout with a retransmission consent deal, restoring service in over 40 markets on July 10, 2026. The company is scheduled to report its Q2 2026 earnings after the market close on August 6, …
SSP
main company
Sharemaestro market context
Price below Trend Line
52 weeks +4.2%
Scripps to release second-quarter 2026 operating results on Aug. 6
The E.W. Scripps Company (NASDAQ: SSP) will announce its second-quarter 2026 operating results after markets close on Thursday, August 6. A conference call with senior management will follow on Friday, August 7, at 9:30 a.m. Eastern time. The company has provided instructions for accessing …
SSP
main company
Sharemaestro market context
Price below Trend Line
52 weeks +4.2%